This Week in Psychedelics

Cybin Inc.'s new drug for treating depression meets major milestone. Plus a new study on DMT and a new effort from congress to protect state and local Government's ability to create their own psychedelic policies.

November 3, 2023

This Week...

Cybin, Inc. announced that a Phase II study for its drug candidate CYB003 met its primary efficacy endpoint in the treatment of major depressive disorder.

Interim data showed that 53.3% of patients responded to the treatment three weeks after a single dose. Patients demonstrated 20% remission versus 0% for those who took a placebo. There were no serious adverse effects reported.

Cybin now expects to have full topline data from the study by Q4 and 12-week durability data in Q1, 2024. The company is also expected to start a Phase III study for the product before Q2, 2024. Here’s more:

A new study from Imperial College London was published showing that extending a DMT journey was safe and well-tolerated by study subjects.

Here’s a snippet of the abstract that was published in the Journal of Psychopharmacology …

In the placebo-controlled study, we investigated a novel method of DMT administration involving a bolus injection paired with a constant-rate infusion, with the goal of extending the DMT experience. Pharmacokinetic parameters of DMT estimated from plasma data of a previous study of bolus intravenous DMT were used to derive dose regimens necessary to keep subjects in steady levels of immersion into the DMT experience over an extended period of 30 min, and four dose regimens consisting of a bolus loading dose and a slow-rate infusion were tested in eleven healthy volunteers. The present method is effective for extending the DMT experience in a stable and tolerable fashion. While subjective effects were maintained over the period of active infusion, anxiety ratings remained low and heart rate habituated within 15 min, indicating psychological and physiological safety of extended DMT. Plasma DMT concentrations increased consistently starting 10 min into DMT administration, whereas psychological effects plateaued into the desired steady state, suggesting the development of acute psychological tolerance to DMT. Taken together, these findings demonstrate the safety and effectiveness of continuous IV DMT administration, laying the groundwork for the further development of this method of administration for basic and clinical research.

You can read more about the results of this study here:

A pair of congressmen filed an amendment to a large-scale spending bill that would prohibit the use of federal funds to interfere with state and local laws allowing the use and sale of psilocybin for medical purposes.

Reps. Robert Garcia and Earl Blumenauer are seeking to attach the psychedelics measure to appropriations legislation covering Commerce, Justice, Science, and related agencies. It will be up to the House Rules Committee to determine whether the amendment will reach a floor vote. Check it out:

Did You Know?

Did you know that LSD could help people learn faster when receiving feedback and enhance exploratory behavior?

According to a study published in Psychological Medicine, LSD can increase the speed at which participants update their expectations based on feedback, making them quicker to learn from their experiences than those who took a placebo.

In addition, those who took LSD were more exploratory in their behavior, meaning that they were more likely to try new options when making decisions. By enhancing the rate at which people learn from feedback and increasing exploratory behavior, LSD may help individuals with mental health issues break free from negative thought patterns and develop new, more positive associations. Here’s more: